期刊文献+

Vav1蛋白在非小细胞肺癌浸润T细胞中的表达及意义 被引量:2

The significance and expression of Vav1 in infiltrating T lymphocytes from nonsmall cell lung cancer
下载PDF
导出
摘要 目的:探讨Vav1蛋白在非小细胞肺癌(Nonsmall cell lung cancer,NSCLC)浸润T淋巴细胞中的表达及其临床病理意义。方法:收集天津医科大学附属肿瘤医院肺外科手术切除的新鲜肺癌标本40例,分离出肿瘤浸润T淋巴细胞(Tumor infiltrating lymphocyte,TIL-T),通过RT-PCR方法检测TIL-T中Vav1基因水平的表达;Western blot检测Vav1蛋白表达情况。并且总结40例患者的临床病理特征,SPSS17.0软件对数据进行统计分析,采用独立样本t检验及ANOVA方差分析法,分析TIL-T中Vav1的表达与NSCLC临床病理特征的关系。结果:TIL-T中Vav1的表达与NSCLC组织的分化程度和淋巴结转移相关(P<0.05),而与年龄、性别、组织类型和临床分期无相关性(P>0.05)。高、中、低分化组的肺癌标本TIL-T中Vav1基因的表达量2-△CT值分别为0.113±0.097,0.055±0.050及0.029±0.022,三组比较有差异(P=0.007);且三组肺癌标本TIL-T中Vav1蛋白的IOD值分别为0.543±0.323,0.425±0.331及0.153±0.150,差异有统计学意义(P=0.010)。有淋巴结转移组及无淋巴结转移组肺癌标本TIL-T中Vav1基因的表达量2-△CT值分别为0.039±0.051及0.072±0.059,两组比较有差异(P=0.048);且两组肺癌标本TIL-T中Vav1蛋白的IOD值分别为0.229±0.205及0.454±0.324,差异有统计学意义(P=0.024)。结论:TIL-T中Vav1的表达水平与NSCLC的生物学行为密切相关,有助于判断预后。TIL-T中Vav1表达水平与肿瘤分化程度呈正相关,与淋巴结转移率呈负相关。提示肺癌组织局部免疫耐受可能与TIL-T中Vav1表达水平降低有关,Vav1是评价NSCLC患者T细胞功能以及局部免疫状态的指标之一。 Objective:To explore the expression and clinicopathological significance of Vavl in the infiltrating T lymphocytes of nonsmall cell lung cancer patients. Methods :40 operated NSCLC patients were involved2 Tumor infiltrating T lymphocytes (TIL-T) were separated from nonsmall cell lung cancer tissues. The expression levels of Vavl in TIL-T were detected by RT-PCR and Western blot respectively. We also summarized the clinicopathological characteristics of the patients with NSCLC and analyzed the correlations between the expression of Vavl in TIL-T and these various clinicopathological parameters. The SPSS17.0 software was used for statisti- cal analysis. The independent sample t-test and ANOVA variance analysis were used to analyse the relationship between the expression of Vavl in TIL-T and the clinicopathologieal characteristics of the patients with NSCLS. Results:The expression levels of Vavl in TIL- T were associated significantly with degree of differentiation in NSCLC' and lymph node metastasis (P 〈 0.05), but were not associated with age, gender, histology and clinical stage (P 〉 0.05 ). The expression quantity of Vavl gene in TIL-T from well, moderate and poor differentiation lung cancer specimens was 0. 113 ±0. 097,0. 055±0. 050 and 0. 029 ±0. 022, respectively. There was difference among three groups(P = 0. 007). And IOD value of Vavl protein in TIL-T from well, moderate and poor differentiation lung cancer specimens was 0. 543±0. 323,0. 425 ±0. 331 and 0. 153 ±0. 150. The difference had statistical significance(P =0. 010). The ex- pression quantity of Vavl gene in TIL-T from the groups with and without lymph node metastasis was 0. 039± 0. 051 and 0. 072±0. 059, respectively. There was difference between two groups ( P = 0. 048 ). And IOD value of Vavl protein in TIL-T from the two groups was 0.229±0. 205 and 0. 454 ± 0. 324, respectively. There was statistical significance difference( P = 0. 024). Conclusion: The expression levels of Vavl in TIL-T are closely associated with biological behavior of NSCLC. This study demonstrates that the local immune tolerance state of lung cancer tissues might associated with the lower expression levels of Vavl in TIL-T. Vavl may be an im- portant factor to evaluate the local immune state of NSCLC.
出处 《中国免疫学杂志》 CAS CSCD 北大核心 2013年第3期279-282,共4页 Chinese Journal of Immunology
基金 天津市自然科学基金项目(11JCYBJC13200)资助
关键词 Vav1 非小细胞肺癌 肿瘤浸润T淋巴细胞 免疫耐受 Vavl NSCLC Tumor infiltrating lymphocyte Immune tolerance
  • 相关文献

参考文献12

  • 1Eerola A K, Soini Y, PaakkoP. A high number of tumor-infiltrating lymphoeytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma [ J ]. Clin Cancer Res, 2000; 6 (5): 1875-1881.
  • 2Hiraoka K, Miyamoto M, Cho Yet al. Concurrent infiltration by CD8 +T cells and CD4+ T cells is a favourable prognostic factor in non-small-Cell lung carcinoma [ J ]. Br J Cancer, 2006; 94 ( 2 ) : 275 -280.
  • 3Miller C H, Graham L, Bear H D. Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma [J]. BMC Immunol, 2010;11:54-54.
  • 4Chen C H, Martin V A, Gorenstein N Met al. Two closely spaced tyrosines regulate NFAT signaling in B cells via Syk association with Vav [ J ]. Mol Cell Biol, 2011 ; 31 ( 14 ) : 2984-2996.
  • 5Ilan L, Katzav S. Human Vavl expression in hematopoietic and canc- er cell lines is regulated by c-Myb and by CpG methylation [ J ]. PLoS One, 2012; 7 (1): e29939.
  • 6Chang J W, Koike T, Iwashima M. hnRNP-K is a nuclear target of TCR-activated ERK and required for T-cell late activation [ J ]. Int Immunol. 2009:21 (12):1351-1361.
  • 7秦誉,耿敬姝,张大川.肿瘤浸润淋巴细胞在结直肠癌中的临床病理分析[J].世界华人消化杂志,2009,17(33):3408-3413. 被引量:6
  • 8Aoyagi K, Minashi K, Igaki Het al. Artificially induced epithelial- mesenchymal transition in surgical subjects: its implications in clini- cal and basic cancer research[J]. PLoS One, 2011 ; 6(4) :e18196.
  • 9Nakano T, Oka K , Takahashi T et al. Roles of Langerhans'cells and T-lymphocytes infiltrating cancer tissues in patients treated by radia- tion therapy for cervical cancer[ J]. Cancer, 1992 ; 70 : 2839-2844.
  • 10Le Page C, Marineau A, Bonza P K et al. BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis[]]. PLoS One, 2012; 7(6) : e38541.

二级参考文献36

  • 1Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299-308.
  • 2Heemskerk B, Liu K, Dudley ME, Johnson LA, Kaiser A, Downey S, Zheng Z, Shelton TE, Matsuda K, Robbins PF, Morgan RA, Rosenberg SA. Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther 2008; 19:496-510.
  • 3Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009; 21:233-240.
  • 4Becher B, Bechmann I, Greter M. Antigen presentation in autoimmunity and CNS inflammation: how T lymphocytes recognize the brain. J Mol Med 2006; 84:532-543.
  • 5Loose D, Van de Wiele C. The immune system and cancer. Cancer Biother Radiopharm 2009; 24:369-376.
  • 6Ohta T, Elnemr A, Kitagawa H, Kayahara M, Takamura H, Fujimura T, Nishimura G, Shimizu K, Yi SQ, Miwa K. Fas ligand expression in human pancreatic cancer. Oncol Rep 2004; 12:749-754.
  • 7Lim SC. Fas-related apoptosis in gastric adenocarcinoma. Oncol Rep 2003; 10:57-63.
  • 8Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der Hulst JM, Drijfhout JW, Melief CJ, Kenter GG, Fleuren GJ, Offringa R, van der Burg SH. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 2007; 67:354-361.
  • 9Tomsova M, Melichar B, Sedlakova I, Steiner I. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 2008; 108:415-420.
  • 10Nelson BH, The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev 2008; 222: 101-116.

共引文献5

同被引文献13

  • 1Yang L. Incidence and mortality of gastric cancer in China[J].World J Gastroenterol,2006,12(1):17-20. doi:10.3748/wjg.v12.i1.17.
  • 2Helou YA,Petrashen AP,Salomon AR. Vav1 regulates T- cellactivation through a feedback mechanism and crosstalk between theT-cell receptor and CD28[J]. J Proteome Res,2015,14(7):2963-2975. doi:10.1021/acs.jproteome.5b00340.
  • 3Lazer G, Katzav S. Guanine nucleotide exchange factors forRhoGTPases:good therapeutic targets for cancer therapy-[J]. CellSignal,2011,23(6):969-979. doi:10.1016/j.cellsig.2010.10.022.
  • 4Fernandez-Zapico ME,Gonzalez-Paz NC,Weiss E,et al. Ectopicexpression of VAV1 reveals an unexpected role in pancreaticcancer tumorigenesis[J]. Cancer Cell,2005,7(1):39-49. doi:10.1016/j.ccr.2004.11.024.
  • 5Fischer KD,Kong YY,Nishina H,et al. Vav is a regulator ofcytoskeletal reorganization mediated by the T- cell receptor[J].Curr Biol,1998,8(10):554-562.
  • 6Lazer G,Idelchuk Y,Schapira V,et al. The haematopoietic specificsignal transducer Vav1 is aberrantly expressed in lung cancer andplays a role in tumourigenesis[J]. J Pathol,2009,219(1):25-34.doi:10.1002/path.2579.
  • 7Oberley MJ,Wang DS,Yang DT. Vav1 in hematologic neoplasms,a mini review[J]. Am J Blood Res,2012,2(1):1-8.
  • 8Hornstein I,Pikarsky E,Groysman M,et al. The haematopoieticspecific signal transducer Vav1 is expressed in a subset of humanneuroblastomas[J]. J Pathol,2003,199(4):526-533. doi:10.1002/path.1314.
  • 9Qi Y,Kong FM,Deng Q,et al. Clinical significance and prognosticvalue of Vav1 expression in Non-small cell lung cancer[J]. Am JCancer Res,2015,5(8):2491-2497.
  • 10Grassilli S ,Brugnoli F ,Lattanzio R ,et al. High nuclear level ofVav1 is a positive prognostic factor in early invasive breast tumors:a role in modulating genes related to the efficiency of metastaticprocess[J]. Oncotarget,2014,5(12):4320-4336. doi:10.18632/oncotarget.2011.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部